Tuesday May 14
BioMarin Pharmaceutical Inc. to Present at the UBS Global Healthcare Conference
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! SAN RAFAEL, Calif., May 14, 2013 -- BioMarin Pharmaceutical Inc.
Mon May 13, 2013
Biomarin Pharm PT Raised to $75.00
The firm currently has a "hold" rating on the stock. Shares of Biomarin Pharm traded up 1.73% during mid-day trading on Monday, hitting $68.85. Biomarin Pharm has a one year low of $33.75 and a one year high of $66.63. The stock's 50-day moving average is currently $62.1. The company's market cap is $9.571 billion.
Sat May 11, 2013
Biomarin Pharm Now Covered by Goldman Sachs
The firm set a "buy" rating on the stock. A number of other analysts have also recently weighed in on BMRN.
Fri May 10, 2013
Today's Research on DCTH, AKRX, ASTX, BMRN, and FRX
StockCall.com Provides Stock Research on Delcath Systems Inc., Akorn Inc., Astex Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., and Forest Laboratories Inc.
Thu May 09, 2013
The Business Journal
BioMarin loss widens as R&D costs increase
BioMarin Pharmaceutical Inc. recently reported a net loss of $39.8 million, or 31 cents per share, for the first quarter ended March 31, compared to a net loss of $24 million in the same period last year.
Sun May 05, 2013
Biomarin Pharm Stock Rating Reaffirmed by Zacks
's stock had its "neutral" rating reiterated by Zacks in a research note issued to investors on Tuesday, AnalystRatingsNetwork reports.
Wed May 01, 2013
Why BioMarin, Catalyst Pharmaceutical Partners And Vertex Are Expected To Outperform
Recently, shares of Catalyst Pharmaceutical Partners and Vertex Pharmaceuticals spiked dramatically upward, drawing the attention of many traders and investors.
Tue Apr 30, 2013
The Business Journal
FDA approves Raptor drug for rare disease
Raptor Pharmaceutical Corp. today said the U.S. Food and Drug Administration approved its drug designed for the treatment of nephropathic cystinosis, a rare and possibly life-threatening metabolic disorder.
Celsion Corporation Strengthens Board of Directors With Addition of Pharma/Biotech Industry Veteran
Celsus Therapeutics , an emerging growth, development-stage biotech company, announced the addition of Pharma/Biotech industry veteran Fredric Price to the Company's Board of Directors.
Fri Apr 26, 2013
Biomarin Pharm Price Target Increased to $66.00 by Analysts at RBC Capital
The firm currently has an "outperform" rating on the stock. Shares of Biomarin Pharm traded up 0.49% during mid-day trading on Friday, hitting $63.18. Biomarin Pharm has a one year low of $33.75 and a one year high of $66.63. The stock's 50-day moving average is currently $62.1. The company's market cap is $7.967 billion.
Thu Apr 25, 2013
BioMarin Pharmaceutical Management Discusses Q1 2013 Results - Earnings Call Transcript
Good day, ladies and gentlemen, and thank you for your patience. You've joined the BioMarin Pharmaceutical First Quarter 2013 Financial Results Conference Call.
Marin Independent Journal
BioMarin Pharmaceutical attributes larger loss in first quarter to growing pains
San Rafael-based BioMarin Pharmaceutical Inc. on Thursday announced a net loss of $39.8 million for the first quarter of 2013 compared with a net loss of $24 million for the first quarter of 2012.
Biomarin Pharm (BMRN) Posts Quarterly Results
Biomarin Pharm posted its quarterly earnings results on Thursday. The company reported earnings per share for the quarter, missing the analysts' consensus estimate of by $0.01, Stock Ratings Network.com reports.